Navigation Links
BIO-key(R) Announces Fourth Quarter and 2008 Year-End Earnings Release and Conference Call Schedule
Date:2/21/2009

WALL, N.J., Feb. 18 /PRNewswire-FirstCall/ -- BIO-key International, Inc. (OTC Bulletin Board: BKYI) today announced plans to release fourth quarter 2008 financial results on Tuesday, February 24, 2009 before the market opens. In conjunction with the release, BIO-key has scheduled a conference call, which will be broadcast live over the Internet on Tuesday, February 24, 2009 at 10:00 a.m. Eastern Time.

          What:      BIO-key International, Inc. Fourth Quarter 2008 Earnings
                     Conference Call
          When:      Tuesday, February 24, 2009 - 10:00 a.m. Eastern Time
          Where:     Live via phone by dialing 303-262-2211 and asking for
                     the BIO-key call at least 10 minutes prior to the start
                     time.  Or live over the Internet by logging on to the web
                     address below.
          Where:    http://www.bio-key.com

A telephonic replay of the conference call will be available through 11:59 p.m. Eastern Time on March 3, 2009 and may be accessed by calling 303-590-3000 and using the passcode 11126733#. Also, an archive of the webcast will be available shortly after the call on www.bio-key.com for a period of three months.

About BIO-key

BIO-key International, Inc., headquartered in Wall, New Jersey, develops and delivers advanced identification solutions and information services to law enforcement departments, public safety agencies, and government and private sector customers. BIO-key's mobile wireless technology provides first responders with critical, reliable, real-time data and images from local, state and national databases. BIO-key's high performance, scalable, cost-effective and easy-to-deploy biometric finger identification technology accurately identifies and authenticates users of wireless
'/>"/>

SOURCE BIO-key International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. BIO-key(R) Fingerprint Biometrics Media Spotlights
2. BIO-key(R) Mobile Data and Messaging Solutions Link Nebraska Law Enforcement Agencies
3. Texas College Police Unit Deploys BIO-key(R) Mobile Data System
4. BIO-key(R) Granted Patent to Secure Biometric Enrollments From Unauthorized Use
5. BIO-key(R) Awarded PocketCop(R) Contracts From Major Law Enforcement Agencies
6. identiMetrics & BIO-key(R) Provide Biometric Finger Scanning for School Food Service Nationwide
7. BIO-key(R) Granted Additional Patent for Biometric Security Solution
8. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
9. Sig-Tec(R) and BIO-key(R) Deliver Advanced Biometric Security Solution to Ohio County Law Enforcement Agency
10. Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification
11. BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):The Academy of Natural Sciences and Temple Press revive rare natural history work in new book 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 57764 1GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 57764 2GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 57764 3ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 1ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 2ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 1With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 2With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 4With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 5With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 6
Breaking Biology Technology:Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4